Other news to note
Adaptimmune Therapeutics plc, of Oxford, U.K., said it is expanding its T-cell therapy development activities to target certain autoimmune diseases and named P. Julian Dyson to head that effort. Adaptimmune's goal is to restore the function of the immune system and inhibit the autoimmune response by delivering affinity enhanced regulatory T cells, or Tregs, to the site of the disease.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST